DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Nucleic Acid Amplification Testing Market 2014 - 2025" report to their offering.
The global nucleic acid amplification test (NAAT) market is expected to reach USD 4.4 Billion by 2025.
Nucleic acid amplification testing is gaining preference over traditional diagnostic techniques because of its high efficiency and accuracy. In addition, the potential application of these tests in various life-threatening diseases, including several types of cancer, is attracting a large amount of investment for the purpose of R&D. Increasing number of ongoing studies are expected to ensure higher growth rate in the later part of the forecast period.
These tests are currently being used extensively for screening and diagnosis of a wide range of infectious diseases. Along with known infectious diseases, management of epidemics of new diseases has caused a sudden surge in the demand for advanced diagnostic tests. NAAT is currently the most advanced and efficient diagnostic method, which extensively uses technology that helps in reducing procedural time and consumption of reagents.
- Becton, Dickinson and Company
- Hoffmann-La Roche Ltd
- Siemens Healthcare GmbH
- Bio-Rad Laboratories, Inc.
- bioMérieux SA
- Illumina, Inc.
- Grifols SA
- Beckman Coulter, Inc.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
4 Nucleic Acid Amplification Testing: Application Estimates & Trend Analysis
5 Nucleic Acid Amplification Testing: Technique Estimates & Trend Analysis
6 Nucleic Acid Amplification Testing: Regional Estimates & Trend Analysis, by Application, and Techniques
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/lxrlxr/nucleic_acid